deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT02296203

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE

Sponsor: Gruppo Oncologico del Nord-Ovest

Conditions Metastatic Colorectal Cancer
Interventions cetuximab irinotecan
Updated 10 times since 2017 Last updated: Feb 14, 2018 Started: Oct 31, 2014 Primary completion: Jun 19, 2017 Completion: Jun 15, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently ongoing. Gruppo Oncologico del Nord-Ovest leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotRecruiting~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshotCompleted~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Mar 2020 · 21 months · monthly snapshotActive Not Recruiting~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Mar 2020 — Jan 2021 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

▶ Show 5 earlier versions

  1. Jun 2018 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Completed → Active Not Recruiting

  3. Aug 2017 — Oct 2017 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Unknown Status → Recruiting

  5. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gruppo Oncologico del Nord-Ovest
Data source: Gruppo Oncologico del Nord-Ovest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations